Sign In
Last checked at 
16 Apr 2013 07:00
ο»Ώ
For immediate release | 16 April 2013 |
Β
Futura Medical plcΒ
("Futura" or "the Company")
Director Share Dealings
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, received notification on 15 April 2013 from James Barder, the Chief Executive of the Company, that his non-beneficial interest in the Company has increased from 309,000 ordinary shares to 352,500 ordinary shares as a result of a purchase, by a family trust of which Mr Barder is a trustee, of 43,500 ordinary shares at 65 pence per share on 15 April 2013.
Β
Mr Barder's aggregate beneficial and non-beneficial holding has therefore increased from 925,330 ordinary shares to 968,830 ordinary shares representing 1.25% of the Company's issued share capital.
Β
Β
Β
For any further information please contact:
Β
Futura Medical plc | Β |
James Barder, Chief Executive | Tel: +44 (0)1483 685 670 |
mail to: james.barder@futuramedical.com | www.futuramedical.com |
Β | Β |
Β Nomura Code Securities Limited | Β |
Phil Walker / Giles Balleny | Tel:+44 (0)20 7776 1200 |
Β Β | Β |
For media enquiries please contact: | Β |
Β | Β |
Buchanan | Β |
Mark Court / Fiona Henson / Sophie Cowles | Tel: +44 (0)20 7466 5000 |
Β
Β
Notes to Editors
Β
Futura Medical plc
Β
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Β
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Β
Follow the stocks
